Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
333.5 CHF | +1.68% | -1.19% | +10.07% |
04-16 | Ypsomed Partners with ten23 health for Wearable Injector Product Commercialization | MT |
04-12 | Dental Equipment Company Straumann Names New Chair | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 52% by 2026.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- With an expected P/E ratio at 59.95 and 43.11 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.07% | 5.03B | B- | ||
-3.79% | 184B | C+ | ||
-0.84% | 108B | C | ||
-3.75% | 67.82B | A | ||
+3.45% | 51.05B | B- | ||
+9.04% | 44.67B | B- | ||
+3.40% | 41.78B | B+ | ||
+3.21% | 26.78B | B | ||
+3.66% | 26.59B | A- | ||
+15.23% | 25.86B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- YPSN Stock
- Ratings Ypsomed Holding AG